Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
United States
UCSF Memory and Aging Center, San Francisco, California Northwestern University, Chicago, Illinois Mayo Clinic, Rochester, Minnesota University of Pennsylvania, Philadelphia, Pennsylvania Houston Methodist Hospital - Nantz National Alzheimer Center, Houston, Texas Last updated October 2025